Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials

被引:148
作者
Bonovas, Stefanos
Filioussi, Kalitsa
Tsavaris, Nikolaos
Sitaras, Nikolaos M.
机构
[1] Univ Athens, Sch Med, Dept Pharmacol, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece
[3] Hellen Ctr Dis Control & Prevent, Dept Epidemiol Surveillance & Intervent, Athens, Greece
关键词
D O I
10.1200/JCO.2006.06.3560
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose A growing body of literature suggests that statins may have chemopreventive potential against cancer. Our aim was to examine the strength of this association through a detailed meta-analysis and meta-regression analysis of randomized controlled trials (RCTs). Methods A comprehensive search for trials published up to 2005 was performed, reviews of each study were conducted, and data were abstracted. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% CIs were calculated using the random- and fixed-effects models. Subgroup, sensitivity, and meta-regression analyses were also conducted. Results Thirty-five RCTs of statins for cardiovascular outcomes contributed to the analysis (n = 109,143). The degree of variability between trials was consistent with what would be expected to occur by chance alone. Statin use was not associated with a substantially increased or decreased overall risk of cancer (RR = 0.99; 95% CI, 0.94 to 1.04). Similarly, statin use did not significantly affect respiratory cancer risk ( RR = 0.95; 95% CI, 0.83 to 1.09). However, the meta-regression analysis indicated that age of study participants modified the association between statin use and cancer risk ( P =.003). Conclusion Our findings do not support a protective effect of statins against cancer. However, this conclusion is limited by the relatively short follow-up periods (4.5 years on average) of the studies analyzed. Thus, it is important to continue monitoring the long-term safety profiles of statins. Until then, physicians need to be vigilant in ensuring that statin use remains restricted to the approved indications.
引用
收藏
页码:4808 / 4817
页数:10
相关论文
共 89 条
[1]  
[Anonymous], 1993, Am J Cardiol, V72, P1031
[2]  
[Anonymous], 2002, JAMA
[3]  
[Anonymous], 2000, ITAL HEART J
[4]  
[Anonymous], METAANALYSIS DECISIO
[5]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[6]   Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease [J].
Beishuizen, ED ;
Van de Ree, MA ;
Jukema, JW ;
Tamsma, JT ;
Van der Vijver, JCM ;
Meinders, AE ;
Putter, H ;
Huisman, MV .
DIABETES CARE, 2004, 27 (12) :2887-2892
[7]   A comparison of observational studies and randomized, controlled trials. [J].
Benson, K ;
Hartz, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1878-1886
[8]   Do statins cause cancer? A meta-analysis of large randomized clinical trials [J].
Bjerre, LM ;
LeLorier, J .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (09) :716-723
[9]   3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].
Blais, L ;
Desgagné, A ;
LeLorier, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368
[10]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976